



OFFICIAL

OBSTETRICS AND GYNAECOLOGY CLINICAL PRACTICE GUIDELINE	
<h1>Magnesium Sulfate for Neuroprotection of the Fetus</h1>	
Scope (Staff):	WNHS obstetrics and midwifery staff
Scope (Area):	Obstetrics and Midwifery clinical areas at KEMH and OPH
This document should be read in conjunction with the Disclaimer .	

Aim

To reduce the incidence of cerebral palsy as a complication of very preterm birth by the administration of magnesium sulfate (MgSO_4) in preterm labour.

Key points

1. MgSO_4 is given to women who are at imminent risk of early preterm birth, and are less than 30 weeks gestational age (i.e. 29^{+6} or less weeks), to achieve a degree of neuro protection of the fetus.
2. MgSO_4 should be given when early preterm birth (less than 30 weeks) is planned or definitely expected within 24 hours. In the planned birth, it is recommended MgSO_4 be commenced 4 hours prior to delivery.
3. In the unplanned delivery, MgSO_4 should only be given when the woman is in active preterm labour, with the patient in Labour and Birth Suite (L&BS).
4. MgSO_4 for neuroprotection should be given in pregnancies less than 29^{+6} , regardless of whether pregnancy is single or multiple, regardless of parity, regardless of anticipated mode of delivery and whether or not corticosteroids have been given.
5. Regimen for the administration of MgSO_4 is 4 g over a 20-minute period, continue at 1 g/hour for 4 hours then cease infusion – see algorithm over the page. To be read in conjunction with the [WNHS Magnesium Adult Medication Monograph](#). If the birth occurs before the 4-hour mark, discontinue the infusion at the time of birth.
6. Urgent delivery for fetal or maternal indications should not be delayed in order to achieve MgSO_4 administration.



Procedure to administer magnesium sulfate for neuroprotection

Prior to commencement of magnesium sulfate (MgSO₄)

- Provide information to the woman about the use of MgSO₄
- Obtain verbal consent
- Two registered midwives and/or medical practitioners must:
 1. Check the correct medication, dose and infusion rate
 2. Set up the infusion line and pump
- Baseline observations prior to MgSO₄ Loading Dose regime i.e. pulse, blood pressure (BP), respiratory rate (RR), SpO₂, and deep tendon/patella reflexes.
- Before commencing infusion, check and document:
 - the deep tendon/patella reflex is present
 - the respiration rate is greater than 12 respirations per minute
- Commence the infusion - **always use an infusion pump.**



MgSO₄ loading dose regimen

- Infuse 4 g of MgSO₄ over 20 minutes.
- This equates to an infusion rate of **150 mL per hour for 20 minutes/ the woman receives only 50 mL of the infusion.**
- A solution of 8 g of MgSO₄ in a 100 mL bag is used at KEMH.
- **Always use an infusion pump.**



MgSO₄ maintenance regimen

- The dose for maintenance infusion is 1 g of MgSO₄ per hour for **4 hours**.
- Although 4 hours is ideal, this should NOT delay delivery of a preterm baby.
- It is better to deliver the baby in-hours, so 1 hour of MgSO₄ will suffice in such circumstances
- This equates to an **infusion rate of 12.5 mL per hour** where the solution of 8 g of MgSO₄ in 100 mL bag is used at KEMH.
- **Always use an infusion pump.**



Maternal observations

- Monitor deep tendon/patella reflexes, RR and BP every **15 minutes** for the first **two** hours, then hourly.
- Monitor Oxygen saturations continuously with a pulse oximeter and record hourly
- Measure and record urine hourly- ensure output is over > 25 mL/ hr.



When to cease infusion and notify Medical Officer

- If deep tendon/patella reflexes are absent
- If respirations are less than 12 respirations per minute
- If urine output is less than 25 mL/ hr
- If a major side effect is witnessed, such as respiratory depression.

Additional information

1. MgSO₄ is only given to women who are at imminent risk of delivery of a preterm infant of less than 30 weeks gestation and birth is planned or definitely expected within 24 hours. Ideally it should be commenced **4 hours prior** to delivery.
2. Urgent delivery for fetal or maternal indications should not be delayed in order to achieve MgSO₄ administration.
3. Calcium gluconate 1 g in 10 mL must be available at all times for treatment of MgSO₄ toxicity. Resuscitation equipment should be readily available.
4. Apply continuous fetal monitoring.
5. Be aware nifedipine increases the effect of magnesium sulfate and the risk of hypotension.

Prescribing

How to prescribe LOADING dose:

KE011 11/22 DO NOT WRITE IN BINDING MARGIN

Magnesium Sulfate for Neuroprotection

Women and Newborn Health Service

INTRAVENOUS FLUID & ADDITIVE ORDER FORM

Year: 20____ Chart ____ of ____

Site: KEMH ☐ OPH ☐

ALLERGIES AND ADVERSE DRUG REACTIONS
Nil known Unknown Yes – Refer to WA HMC
Attached ADR Sticker

Ward: _____ Weight: _____

Med Rec. No: _____
Surname: _____
Forename: _____
Gender: _____ D.O.B. _____

Date	Type of Fluid	Volume (mL)	Rate (mL/hr)	Additive & Dose	To start	Prescriber	Started	Finished	Administered by:	Checked by:
Date	Water for injection	50 mL	150 mL/hr	Magnesium sulfate 4 g	Date: Date Time: Time	Name: A.Doctor Sign: AD	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:

How to prescribe MAINTENANCE dose:

Date	Type of Fluid	Volume (mL)	Rate (mL/hr)	Additive & Dose	To start	Prescriber	Started	Finished	Administered by:	Checked by:
Date	Water for injection	50 mL	12.5 mL/hr	Magnesium sulfate 4 g	Date: Date Time: Time	Name: A.Doctor Sign: AD	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:

See [Appendix 1 for WNHS Intravenous Fluid & Additive Order Form](#) example

Procedure

1. Prior to commencement of MgSO_4 , assess the woman in threatened preterm labour or preterm labour. See [WNHS Preterm Labour guideline](#).
2. Confirm gestational age from previous ultrasound scanning or if no early scan available, from LMP if this is felt to be accurate. In the unbooked patient, who has had no antenatal care, a late scan may be used to determine gestational age.
3. If the patient is less than 30 weeks, determine if delivery is considered to be imminent i.e. evidence of cervical dilatation, ongoing contractions which are not settling with tocolysis and / or there is evidence of progressive effacement and dilatation.
4. Discuss with Obstetric consultant for L&BS/senior registrar/level 4 registrar or above.
5. Transfer the patient to the Labour and Birth Suite (L&BS) as per the management of preterm labour and commence the administration of MgSO_4 .
6. Clinical care of the woman and fetus as outlined below
7. In the case of a planned preterm (<30 weeks gestation) delivery, transfer the patient to Labour and Birth Suite or the Adult Special Care Unit (ASCU), whichever is most appropriate and commence MgSO_4 regime 4 hours prior to anticipated time of delivery.

Antenatal magnesium sulfate infusion

- The solution used at KEMH is 8 g of MgSO₄ in a 100 mL pre-packaged solution. This must be given via an infusion device.
- Administer intravenous **loading bolus dose of 4 g of MgSO₄ over 20 minutes** via a controlled infusion device. This equates to an infusion rate of 150 mL/hour for 20 minutes (i.e. the woman only receives 50 mL)
- See [Appendix 1 - IV Magnesium Sulphate order form](#) as example of how to prescribe.
- Be aware nifedipine increases the effect of magnesium sulfate and the risk of hypotension.
- The loading dose is followed by a maintenance infusion of 1 g of MgSO₄ per hour. When the rate is changed to the maintenance rate, the rate shall be checked and confirmed by two (2) Registered Midwives. This equates to an infusion rate of 12.5 mL per hour.
- Continue at 1 g/hour for 4 hours then cease MgSO₄ infusion. If the birth occurs before the 4-hour mark, discontinue the infusion at the time of birth.
- Prior to the commencement of MgSO₄ infusion:
 - Document a set of baseline observations i.e. pulse, blood pressure (BP), respiratory rate (RR), SpO₂, deep tendon/patella reflexes
 - Ensure deep tendon/patella reflexes are present
 - Ensure respirations are greater than 12 respirations per minute
 - The correct order, medication, dose, and infusion rate is checked by two (2) registered midwives.
- Calcium Gluconate 1 g in 10 mL (2.2 mmol calcium in 10 mL) must be available at all times for treatment of MgSO₄ toxicity.
 - Dose – administer ONE ampoule of Calcium gluconate 1 g in 10 mL (2.2 mmol calcium in 10 mL) intravenously (IV) slowly. Administration must be authorised by a medical officer.
 - ECG monitoring is recommended if Calcium gluconate is given
- Apply continuous fetal monitoring.

Maternal observations

Patella reflexes

- Perform every 15 minutes for the first 2 hours, then hourly thereafter.
- If patella reflexes are absent:
 - Cease the infusion
 - Notify the medical officer
 - Collect blood for serum Magnesium levels

Respiratory rate and oxygen saturation monitoring

- Monitor respirations 15 minutely during the first 2 hours, then hourly thereafter.
- If respirations are less than 12 /minute:
 - Notify the medical officer
 - Cease the infusion until medical review
 - Place the woman in the recovery position
 - Maintain the airway and administer O₂ at 6-8 L/minute
 - Administer IV Calcium gluconate 1 g in 10 mL (2.2 mmol calcium in 10 mL) slowly
 - Monitor heart rate with an ECG if available, or apply as soon as possible.
 - Collect blood for serum magnesium levels
- Monitor maternal O₂ saturation levels continuously with a pulse oximeter.
 - Record O₂ saturation levels hourly
- If respiratory arrest occurs:
 - Stop infusion
 - Call a code blue medical
 - Initiate respiratory support until the woman is intubated and ventilated

Monitor urine output

- Measure and record urine output hourly.
- If urine output is <25 mL/hour:
 - Notify the medical staff

Blood pressure

- Monitor BP 15 minutely during the infusion for the first 2 hours, thereafter hourly.

Review of MgSO₄ infusion

- Report any side effects of MgSO₄ to the medical officer.









Reference

1. Shepherd, E. S., Goldsmith, S., Doyle, L.W., Middleton, P., Marret, S., Rouse, D.J., Pryde, P., Wolf, H.T., & Crowther, C.A. (2024). Magnesium Sulfate Before Preterm Birth for Neuroprotection: An Updated Cochrane Systematic Review. *Obstetrics & Gynecology* 144(2), 161-170. DOI: [10.1097/AOG.0000000000005644](https://doi.org/10.1097/AOG.0000000000005644)

Related WNHS procedures and guidelines

[WNHS Obstetrics and Gynaecology Clinical Practice Guideline: Preterm Labour](#)

Magnesium Sulfate for Neuroprotection of the Fetus

Keywords:	neuroprotection, magnesium sulphate, magnesium sulphate neuro protection, fetal neuro protection, magnesium sulphate infusion, preterm, magnesium sulfate		
Document owner:	Obstetrics and Gynaecology Directorate		
Author / Reviewer:	Head of Department, Obstetrics KEMH		
Date first issued:	Sept 2010(v1)	Version:	7.1
Reviewed dates:	Sept 2014(v2), May 2015 (v3- amended), Apr 2016 (v4), Sept 2016(v5), Dec 2024(v6), June 2025 (v7 & v7.1- amend formatting)	Next review date:	Jun 2028
(v7) Approved by:	Medicines and Therapeutics Committee (MTC) - out of session approval of amendment	Date:	06/03/2025
	HoD, Codirector or Coordinator of Nursing/Midwifery	Date:	04/06/2025
(v6) Endorsed by:	Midwifery and Obstetrics Clinical Practice and Outcomes Committee	Date:	04/12/2024
NSQHS Standards (v2) applicable:	<div><div><input checked="" type="checkbox"/>  1: Clinical Governance</div><div><input type="checkbox"/>  2: Partnering with Consumers</div><div><input type="checkbox"/>  3: Preventing and Controlling Healthcare Associated Infection</div><div><input checked="" type="checkbox"/>  4: Medication Safety</div></div>	<div><div><input type="checkbox"/>  5: Comprehensive Care</div><div><input type="checkbox"/>  6: Communicating for Safety</div><div><input type="checkbox"/>  7: Blood Management</div><div><input type="checkbox"/>  8: Recognising and Responding to Acute Deterioration</div></div>	
<div>Printed or personally saved electronic copies of this document are considered uncontrolled.</div> <div>Access the current version from WNHS HealthPoint.</div>			

Version history

Number	Date	Summary
1-5	Prior to Dec 2024	Archived- contact OGD Guideline Coordinator for previous versions. Original titled as B.2.5.3: 'Antenatal Magnesium Sulphate Prior to Preterm Birth for Neuro Protection of the Fetus Post Birth'
6	Dec 2024	<ul style="list-style-type: none"> Minor amendment to drug dosage values; Clarity to drug clinical indicators for Nifedipine administration and side effects; Flow chart reviewed. Emphasised a set timeline for medication should NOT delay delivery of a preterm baby. IV Magnesium Sulphate order form added as appendix example. Prepopulated intravenous additive form developed by Pharmacy and included within the Guideline and also as an appendix.
7	June 2025	<ul style="list-style-type: none"> Prescription example images amended (on page 3 and appendix 1)
7.1	26/06/2025	<ul style="list-style-type: none"> Minor amendment- sentence formatting - dot point on p5 reformatted

This document can be made available in alternative formats on request for a person with a disability.


© North Metropolitan Health Service 2025

Copyright to this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the *Copyright Act 1968*, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.

Appendix 1 – IV Magnesium Sulfate order form

KE011
11/22

DO NOT WRITE IN BINDING MARGIN



EMR305620

Magnesium Sulfate for Neuroprotection

ALLERGIES AND ADVERSE DRUG REACTIONS

Nil known Unknown Yes – Refer to WA HMC

Attached ADR Sticker

Med Rec. No:

Surname:

Forename:

Gender: D.O.B.

Women and Newborn Health Service

INTRAVENOUS FLUID & ADDITIVE ORDER FORM

Year: 20____ Chart ____ of ____

Site: KEMH ☐ OPH ☐

Ward:

Weight:

Date	Type of Fluid	Volume (mL)	Rate (mL/hr)	Additive & Dose	To start	Prescriber	Started	Finished	Administered by:	Checked by:
Date	Water for injection	50 mL	150 mL/hr	Magnesium sulfate 4 g	Date: Date Time: Time	Name: A.Doctor Sign: AD	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
Date	Water for injection	50 mL	12.5 mL/hr	Magnesium sulfate 4 g	Date: Date Time: Time	Name: A.Doctor Sign: AD	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:
					Date: Time:	Name: Sign:	Date: Time:	Date: Time:	Name: Sign:	Name: Sign:

MR740 (KEMH) / MR176.1 (OPH)

INTRAVENOUS FLUID & ADDITIVE ORDER FORM

Page 1 of 1